Physician profile
Michael A Castillo
NPI 1407243033
$1,453.33
in general payments reported to CMS, 2019-2025
25 companies · $286 in 2025
The $286 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39.33 · 2021: $160 · 2022: $417 · 2023: $551 · 2025: $286.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $838.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $837.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $270.84 | 2025 | Inspire |
| Lilly USA, LLC | $130.82 | 2021-2023 | Mounjaro, Jardiance |
| Abbvie INC. | $99.21 | 2023 | Ubrelvy, Vraylar |
| Glaxosmithkline, LLC. | $97.88 | 2021-2023 | Trelegy Ellipta, Arexvy |
| Pfizer INC. | $95.91 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $93.80 | 2022-2023 | |
| Novo Nordisk INC | $85.81 | 2021-2023 | Rybelsus, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $66.52 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $66.38 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $48.25 | 2022-2023 | Breztri |
| Merck Sharp & Dohme LLC | $42.80 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $37.08 | 2023 | Xarelto |
| Idorsia Pharmaceuticals US INC | $33.30 | 2023 | Quviviq |
| Biohaven Pharmaceutical Holding Company LTD. | $33.21 | 2022 | |
| Tactile Systems Technology INC | $32.74 | 2023 | Entre Plus, Flexitouch Plus |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $31.29 | 2022-2023 | Eliquis |
| Takeda Pharmaceuticals U.S.A., INC. | $28.01 | 2022-2023 | Trintellix |
| Pacira Therapeutics, INC. | $26.00 | 2019 | |
| Optinose US, INC. | $25.32 | 2023 | |
| Zogenix INC. | $22.33 | 2021 | |
| Corium, LLC | $20.10 | 2022 | |
| Xeris Pharmaceuticals, INC. | $19.67 | 2022 | |
| Exact Sciences Corporation | $17.18 | 2023 | Cologuard Collection Kit |
| Amgen INC. | $15.74 | 2023 | Otezla, Repatha |
| Mylan Specialty L.P. | $13.14 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Castillo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.